Evidence map›Paper›PMID 26496078›Full record

ArticlePloS one2015

Proteomic and Metabolomic Analyses Reveal Contrasting Anti-Inflammatory Effects of an Extract of Mucor Racemosus Secondary Metabolites Compared to Dexamethasone.

Samuel M Meier, Besnik Muqaku, Ronald Ullmann, Andrea Bileck, Dominique Kreutz, Johanna C Mader, Siegfried Knasmüller, Christopher Gerner

Open access · goldAbstract readComparative Study
In one paragraph

Article in PloS one, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.5field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 2 countries.

Samuel M MeierDepartment of Analytical Chemistry, University of Vienna, Währinger Straße 38, 1090, Vienna, Austria.
Besnik MuqakuDepartment of Analytical Chemistry, University of Vienna, Währinger Straße 38, 1090, Vienna, Austria.
Ronald UllmannSyntrion GmbH, Robert-Bosch-Straße 6, 75365, Calw, Germany.
Andrea BileckDepartment of Analytical Chemistry, University of Vienna, Währinger Straße 38, 1090, Vienna, Austria.
Dominique KreutzDepartment of Analytical Chemistry, University of Vienna, Währinger Straße 38, 1090, Vienna, Austria.
Johanna C MaderDepartment of Analytical Chemistry, University of Vienna, Währinger Straße 38, 1090, Vienna, Austria.
Siegfried KnasmüllerInstitute of Cancer Research, Medical University of Vienna, Borschkegasse 8a, 1090, Vienna, Austria.
Christopher GernerDepartment of Analytical Chemistry, University of Vienna, Währinger Straße 38, 1090, Vienna, Austria.
University of Vienna · ATMedical University of Vienna · ATRobert Bosch (Germany) · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Classical drug assays are often confined to single molecules and targeting single pathways. However, it is also desirable to investigate the effects of complex mixtures on complex systems such as living cells including the natural multitude of signalling pathways. Evidence based on herbal medicine has motivated us to investigate potential beneficial health effects of Mucor racemosus (M rac) extracts. Secondary metabolites of M rac were collected using a good-manufacturing process (GMP) approved production line and a validated manufacturing process, in order to obtain a stable product termed SyCircue (National Drug Code USA: 10424-102). Toxicological studies confirmed that this product does not contain mycotoxins and is non-genotoxic. Potential effects on inflammatory processes were investigated by treating stimulated cells with M rac extracts and the effects were compared to the standard anti-inflammatory drug dexamethasone on the levels of the proteome and metabolome. Using 2D-PAGE, slight anti-inflammatory effects were observed in primary white blood mononuclear cells, which were more pronounced in primary human umbilical vein endothelial cells (HUVECs). Proteome profiling based on nLC-MS/MS analysis of tryptic digests revealed inhibitory effects of M rac extracts on pro-inflammatory cytoplasmic mediators and secreted cytokines and chemokines in these endothelial cells. This finding was confirmed using targeted proteomics, here treatment of stimulated cells with M rac extracts down-regulated the secretion of IL-6, IL-8, CXCL5 and GROA significantly. Finally, the modulating effects of M rac on HUVECs were also confirmed on the level of the metabolome. Several metabolites displayed significant concentration changes upon treatment of inflammatory activated HUVECs with the M rac extract, including spermine and lysophosphatidylcholine acyl C18:0 and sphingomyelin C26:1, while the bulk of measured metabolites remained unaffected. Interestingly, the effects of M rac treatment on lipids were orthogonal to the effect of dexamethasone underlining differences in the overall mode of action.

Indexed as

Amino Acid SequenceAnti-Inflammatory AgentsBiological ProductsCells, CulturedChromatography, LiquidCytokinesDexamethasoneElectrophoresis, Gel, Two-DimensionalHep G2 CellsHumansHuman Umbilical Vein Endothelial CellsInflammation MediatorsLeukocytes, MononuclearMetabolomicsMolecular Sequence DataMucorAnti-Inflammatory AgentsBiological ProductsCytokinesDexamethasoneInflammation MediatorsProteome

Identifiers

PMID26496078
PMCPMC4619718
OpenAlexW2157723081

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.